Volume 94, Issue 3, Pages (September 2018)

Slides:

Advertisements

Similar presentations

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.

Advertisements

When Using DOPPS Slides. DOPPS Slide Use Guidelines.

Vitamin D levels and patient outcome in chronic kidney disease

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Isolated Systolic Hypertension: An Update After SPRINT

Intensive hemodialysis—keeping the faith

Viper venom for diabetic nephropathy

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

Volume 87, Issue 5, Pages (May 2015)

Regional Differences in the Associations Between Prescribed Dialysate Sodium Concentration and Interdialytic Weight Gain in the Dialysis Outcomes and.

Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study.

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Volume 84, Issue 3, Pages (September 2013)

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Missed Hemodialysis Treatments: International Variation, Predictors, and Outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Issa Al.

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Intensive hemodialysis—keeping the faith

The risk of hospitalization and modality failure with home dialysis

International Differences in the Location and Use of Arteriovenous Accesses Created for Hemodialysis: Results From the Dialysis Outcomes and Practice.

Volume 84, Issue 3, Pages (September 2013)

Volume 87, Issue 1, Pages (January 2015)

Volume 81, Issue 7, Pages (April 2012)

Fig. 2. Evidence-based medication prescriptions

Volume 85, Issue 1, Pages (January 2014)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 80, Issue 9, Pages (November 2011)

Volume 57, Pages S74-S81 (January 2000)

Volume 90, Issue 3, Pages (September 2016)

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Volume 80, Issue 9, Pages (November 2011)

Volume 81, Issue 11, Pages (June 2012)

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

Volume 72, Issue 12, Pages (December 2007)

Volume 82, Issue 5, Pages (September 2012)

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 92, Issue 2, Pages (August 2017)

Jennifer E. Flythe, Stephen E. Kimmel, Steven M. Brunelli

Interdialytic Weight Gain: Trends, Predictors, and Associated Outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS) Michelle.

Volume 85, Issue 1, Pages (January 2014)

Blood pressure targets in hemodialysis patients

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Vitamin D levels and patient outcome in chronic kidney disease

Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema Harikrishna Makani, MD, Sripal Bangalore, MD, MHA,

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

The future of renoprotection: Frustration and promises

Alternate-day dialysis may be needed for hemodialysis patients

Volume 84, Issue 5, Pages (November 2013)

Isolated Systolic Hypertension: An Update After SPRINT

Volume 64, Issue 4, Pages (October 2003)

Volume 81, Issue 7, Pages (April 2012)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 63, Issue 6, Pages (June 2003)

Volume 73, Issue 5, Pages (March 2008)

Current status of maintenance hemodialysis in Beijing, China

Volume 95, Issue 4, Pages (April 2019)

American Journal of Kidney Diseases

International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes.

Charles A. Herzog Kidney International

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system Victoria A. Kumar, Margo A. Sidell,

Stephen Pastan, J. Michael Soucie, William M. McClellan

Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy Andrea M. Steely, MD, Peter W.

Survival among hemodialysis patients by geographic region in DOPPS 3 (2005–2008), with and without adjustments for patient mix differences. Survival among.

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

Volume 94, Issue 3, Pages 589-598 (September 2018) DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients Angelo Karaboyas, Hairong Xu, Hal Morgenstern, Francesco Locatelli, Michel Jadoul, Kosaku Nitta, Indranil Dasgupta, Francesca Tentori, Friedrich K. Port, Bruce M. Robinson Kidney International Volume 94, Issue 3, Pages 589-598 (September 2018) DOI: 10.1016/j.kint.2018.03.013 Copyright © 2018 International Society of Nephrology Terms and Conditions

Figure 1 Renin angiotensin-aldosterone system inhibitors (RAASi) prescription by region, Dialysis Outcomes and Practice Patterns Study (DOPPS) phase, and time on dialysis. “Other” includes any patients prescribed a RAASi other than an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). A/NZ, Australia/New Zealand. *DOPPS phase 2: 2002–2004; phase 3: 2005–2008; phase 4: 2009–2011; phase 5: 2012–2015; **Incident, on dialysis ≤120 days at study entry; prevalent, on dialysis >120 days at study entry. Kidney International 2018 94, 589-598DOI: (10.1016/j.kint.2018.03.013) Copyright © 2018 International Society of Nephrology Terms and Conditions

Figure 2 Associations between antihypertensive medications and mortality in (a) incident dialysis patients and (b) prevalent dialysis patients. ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio. *Incident, on dialysis ≤120 days at study entry; prevalent, on dialysis >120 days at study entry. Kidney International 2018 94, 589-598DOI: (10.1016/j.kint.2018.03.013) Copyright © 2018 International Society of Nephrology Terms and Conditions